| Capmatinib studied in …STUDIED_INderived51 of 51show fewer |
|---|
| → studied in | NCT05488314Phase 1/Phase 2 · active not recruiting A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03040973Phase 2 · active not recruiting Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02813135Phase 1/Phase 2 · recruiting European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors · 51 trials list this drug (7 active) | — | — | Childhood Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05722886Phase 2/Phase 3 · recruiting DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol · 51 trials list this drug (7 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05642572Phase 2 · recruiting Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) · 51 trials list this drug (7 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03784014Phase 3 · completed Molecular Profiling of Advanced Soft-tissue Sarcomas · 51 trials list this drug (7 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05110196Phase 4 · completed Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04677595Phase 2 · completed Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04741789no longer available Managed Access Programs for INC280, Capmatinib · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03333343Phase 1 · active not recruiting Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC · 51 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06988475Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations · 51 trials list this drug (7 active) | — | — | Neoplasm by Site,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04926831Phase 2 · terminated Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575025completed Special Drug Use-results Surveillance of Tabrecta Tablets · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05243641Phase 1/Phase 2 · terminated Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test · 51 trials list this drug (7 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742349Phase 1 · terminated Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). · 51 trials list this drug (7 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04427072Phase 3 · terminated Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04139317Phase 2 · terminated Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04323436Phase 2 · terminated Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01737827Phase 2 · terminated Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. · 51 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03484923Phase 2 · completed Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma · 51 trials list this drug (7 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05567055Phase 2 · withdrawn Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05435846Phase 1 · terminated Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation · 51 trials list this drug (7 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02414139Phase 2 · completed Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159066Phase 2 · completed LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma · 51 trials list this drug (7 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04816214Phase 3 · terminated Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02386826Phase 1 · completed INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme · 51 trials list this drug (7 active) | — | — | Glioblastoma,Gliosarcoma,Malignant Colorectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02795429Phase 1/Phase 2 · completed Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC · 51 trials list this drug (7 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02335944Phase 1/Phase 2 · terminated Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02019693Phase 2 · completed A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer · 51 trials list this drug (7 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05675683completed Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05154344completed RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02750215Phase 2 · completed A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor · 51 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02323126Phase 2 · terminated Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03647488Phase 2 · completed Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01911507Phase 1 · completed INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01610336Phase 2 · completed A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01324479Phase 1 · completed Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors · 51 trials list this drug (7 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01546428Phase 1 · completed A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors · 51 trials list this drug (7 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925104Phase 1 · completed A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. · 51 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02276027Phase 2 · completed A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer · 51 trials list this drug (7 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02474537Phase 1 · completed INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function · 51 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520752Phase 1 · completed A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors · 51 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02626234Phase 1 · completed A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors · 51 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04460729Phase 2 · withdrawn A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases · 51 trials list this drug (7 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02587650Phase 2 · terminated Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma · 51 trials list this drug (7 active) | — | — | Cutaneous Melanoma,Invasive Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02205398Phase 1 · terminated Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy · 51 trials list this drug (7 active) | — | — | Head and Neck Squamous Cell Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03693339Phase 2 · unknown Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation · 51 trials list this drug (7 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03240393Phase 2 · withdrawn Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) · 51 trials list this drug (7 active) | — | — | Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01870726Phase 1/Phase 2 · terminated Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma · 51 trials list this drug (7 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01072266Phase 1 · completed A Dose-escalation Study in Subjects With Advanced Malignancies · 51 trials list this drug (7 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01964235Phase 2 · withdrawn Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma · 51 trials list this drug (7 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |